BioSpace News Archive

EyePoint Pharmaceuticals, Inc. today announced that it has entered into a lease agreement to to design and construct a 40,000-square-foot manufacturing facility in Northbridge, Massachusetts to support the global manufacturing of programs, including EYP-1901 and YUTIQ.

Compugen Ltd. announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities C-Suite Series to discuss Compugen’s leadership in the DNAM-1 axis.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne muscular dystrophy (Duchenne) is now active and recruiting patients.

iSpecimen Inc. today announced that Tracy Curley, CEO of iSpecimen, will participate in the Sequire Biotechnology Conference to be held virtually on Thursday, February 2, 2023.

Intelligent Bio Solutions Inc. today announced it has successfully completed the review of results from Milestone 7, a phase of its biosensor platform development at the University of Newcastle, Australia, that included testing time-to-result (TTR), sensitivity, and reproducibility.

CytoReason, a leader and pioneer in computational disease modeling, announced an expansion of its collaboration with Sanofi.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that patients with Bardet-Biedl syndrome (BBS) and obesity who participated in the company’s global Phase 3 clinical trial of setmelanotide reported clinically meaningful improvements across multiple health-related quality of life (HRQOL) measures based on an analysis published in the Orphanet Journal of Rare Diseases.

Catalyst Pharmaceuticals, Inc. today announced that it has received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Teva Pharmaceuticals, Inc. (“Teva”) advising that Teva had submitted an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE® in the United States.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental new drug application for AYVAKIT ® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM)

TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy™ (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor.